Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
Sponsor: Chinese University of Hong Kong
Summary
This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.
Official title: A Randomised Trial Investigating The Role of En Bloc Resection of Bladder Tumour Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
440
Start Date
2027-01-01
Completion Date
2030-03-31
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Interventions
ERBT and Adjuvant MMC Therapy
Subject will receive 1-year of Ad-MMC after ERBT
ERBT
Subject will undergo ERBT
Locations (2)
Prince of Wales Hospital
Hong Kong, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong